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Abstract 
Hypersensitivity Pneumonitis (HP) is an immune-mediated syndrome triggered by 
inhalation of a wide variety of allergens, to which individual is previously sensitized. 
More than 200 responsible agents for the disease have already been identified; however, 
HP occurs only in a small number of individuals exposed to causal antigens. Thus, the 
present report provides an overview of antigen´s role in HP, highlighting its diversity, 
research methods and prevention strategies, as also antigen´s eviction impact on disease 
prognosis. 
HP is an underdiagnosed disease, and therefore, it is difficult to accurately estimate its 
incidence. Triggering antigens can be divided into 6 broad categories: bacteria, fungi, 
mycobacteria, animal and plant proteins, chemicals and metals, represented by disease 
prototypes. The identification of causal antigen is a major challenge, being unable to be 
obtained in about 30-60% of cases. The acute form of HP, with early detection and 
immediate eviction of causal antigen, tends to have an excellent prognosis. In the chronic 
form, still remains possible a partial recovery of disease; however, some cases tend to 
progress to fibrosis, even after exposure removal. 
In conclusion, HP diagnosis should be based on a proactive search for potential antigen 
sources, although their identification is hampered by the lack of standardized methods to 
demonstrate the specific antigen sensitization. Antigen avoidance is a critical determinant 
on disease prognosis. 
 
KEYWORDS: Hypersensitivity Pneumonitis, Antigen, Research Methods, Diagnosis, 
Prognosis. 
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Introduction 
Hypersensitivity pneumonitis (HP), also known as extrinsic allergic alveolitis, is an 
immune-mediated syndrome that results from lung parenchyma and small-caliber 
respiratory tract inflammation. This reaction is secondary to a repeated and prolonged 
specific antigens inhalation to which individual is sensitized.1 There are more than 200 
antigens already identified as causal agents of HP, that can be found in workplace, at 
home, and in recreational activities. The huge majority are derived from fungi, bacteria, 
protozoa and animal proteins, or even low molecular weight chemical compounds.2 
Further, clinical presentation and disease progression can be extremely variable, 
depending from the nature of causal agent, exposure duration, and intensity, as well as 
individual host factors.1,3,4 
The incidence and prevalence of HP are difficult to estimate accurately, mostly due to it 
under-diagnosis, which may be partly explained by absence of widely accepted diagnostic 
criteria.3,4 Additionally, HP prevalence varies from country to country (and even within 
the same country), according to geographical conditions, local practices (agricultural and 
industrial) and host risk factors.3,5 For example, epidemiologic data show an incidence of 
HP in Europe ranging from 0.3 up to 0.9 per 100.000 inhabitants.6-8 In fact, the annual 
incidence in Denmark is less than 1 per 100 000 inhabitants,7 while in New Mexico is 
about 30 per 100 000 inhabitants,9 and a prospective study carried out in India revealed 
that HP is the most common interstitial lung disease (47.3% of cases).10 
Several HP diagnostic criteria have been proposed, but none of them has yet been 
validated so far. As such, diagnosis is based on integration of clinical, radiological and 
pathological data.11 Identification of causal antigen is crucial, not only for diagnosis but 
also prevention and even prognosis of disease. However, this issue represents a major 
challenge, mostly due to the lack of standardized techniques.5 
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In this sense, this report aims to provide an overview of antigen´s role in HP, highlighting 
its diversity, research methods and prevention strategies, as also antigen´s eviction impact 
on disease prognosis.  
 
From antigen to disease 
The first descriptions of a pulmonary disease similar to HP, as it is known today, appeared 
in 1713, associated with people who worked with cereals.12 However, it was only in 1932 
that Campbell firstly described Farmer's lung (FL), the disease that became the classic 
example of HP.13 In 1959, the respiratory disease was described in mushroom workers, 
caused by inhalation of compounds contaminated by thermophilic actinomycetes. 14 In 
1960, the disease was described in workers who contact with birds, initially associated 
with ducks and turkeys, and later also with parakeets and pigeons (Bird-breeder's lungs).15 
From this date onwards, other agents were progressively reported as having a direct 
contribution to the onset of this disease, being currently identified more than 200 causal 
antigens.2,3 HP only develops in a small proportion of individuals exposed to causal 
antigens; in fact, when exposed to the same causal agent, most individuals are only 
sensitized, leading to a small increase of lymphocytes locally, but without clinical 
relevance, which suggests the existence of host´s intrinsic factors in its 
pathogenesis.4,5,16,17 (Figure 1) 
The coexistence of triggering (e.g., antigen exposure) and promoting factors, such as 
Major Histocompatibility Complex (MHC II) gene polymorphisms, low molecular 
weight proteasomes, transporters associated with antigen processing-1 (TAP1) or other 
exposures, such as viruses, may lead to the development of an exacerbated immune 
reaction resulting in persistent lung inflammation.3,17 In fact, the inhalation of causal 
antigen leads to an inflammatory reaction, with the release of cytokines and pro-
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inflammatory mediators, among others, type 1 T helper (Th1), tumor necrosis factor-α 
(TNFα), interleukin 12 (IL-12) and interferon gamma (INF-γ).18 Thereafter, the continued 
exposure, local antibody production and/or presence of genetic susceptibility lead to 
critical changes in the lung, namely fibroblast expansion and activation, and extracellular 
matrix deposition.17 (Figure 1)  
An interesting aspect to highlight is that HP is less frequent in cigarette smokers. In fact, 
nicotine is thought to inhibit macrophage activation, and lymphocyte proliferation and 
function, but this does not apply to ex-smokers.19 On the other hand, in smokers who 
develop HP, fibrosing disease with a worse prognosis is more common.20  
Concerning to clinical behavior, HP can be traditionally divided into three distinct 
phenotypes: acute, subacute and chronic (Table 1). There is a considerable controversy 
surrounds this classification, because no widely accepted criteria exist to distinguish the 
various stages. In fact, the subacute form is considered by some authors as a variant of 
acute HP.1,4 Lacasse et al. (2009) performed a cluster analysis suggesting that HP patients 
should be classified into only 1 of 2 categories, based on clinical evaluation, pulmonary 
function tests, and high-resolution computed tomography findings.21 As such, some 
authors have proposed an alternative classification that includes acute or episodic HP, 
chronic HP with acute episodes, and chronic HP without acute episodes.22 More recently, 
Vasakova et al. (2017) proposed a novel HP classification into two main categories: 
acute/inflammatory HP and chronic/fibrotic HP, based on clinical-radiologic-pathologic 
correlation, with a considerable prognostic value.6  
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Antigenic diversity 
As already mentioned, HP may be induced by a wide and growing variety of antigens, 
that can be divided into 6 broad categories: bacteria, fungi, mycobacteria, animal and 
plant proteins, chemicals and metals, represented by disease prototypes.3 (Table 2) 
The list of HP-associated environments is increasing, but in most situations, the disease 
is caused by similar antigens in distinct environments.18 Recently, Millon et al. (2016) 
have shown the existence of common antigenic amino acid sequences in orthologous 
proteins from a fungus belonging to Mucorales order and a Mycobacterium species, each 
one acting as a main etiologic agent of a specific HP form.23 The existence of common 
epitopes in orthologous immunogenic proteins from microorganisms belonging to greatly 
different phylogenetic families explains how, in some cases of HP, a growing number of 
etiologic agents have been found in the same disease.23 HP can effectively arise in any 
environment, including workplace, housing, and recreational activities, where bacteria 
and fungi grow or birds are kept.24 Further, drugs can also cause HP, constituting a non-
inhaling variant of the disease. In fact, the number of HP-associated drugs is increasing, 
with more than 380 drugs already reported; 25-28 therefore, it is extremely relevant to 
exclude this cause, frequently missed. The individuals with higher risk of developing HP 
are those working in agriculture, poultry and livestock industries; workers using fluid 
metals;29-31 cheese, sausages or flour processing;32-34 malt or soy sauce manufacturers. 35 
The risk also increases during wood processing (e.g. cork oak bark) and construction; 
textiles, clothing or plastics manufacturing; and even in individuals who work with paints, 
paint hardeners or other chemical products.36,37 However, in about 30-60% of cases, 
antigen remains hidden or unrecognized, even existing some authors who suggested the 
use of “cryptogenic HP” for such patients.6,38 
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Types of disease according to antigen class 
Bacterial exposure  
Farmer's lung (FL) is considered the HP prototype. Although it is still under-diagnosed, 
this is one of the most prevalent types of disease, and in which bacteria are the most 
common responsible antigens. This form of the disease is triggered by inhalation of 
antigens from housed microorganisms, at high humidity conditions, in hay, straw and 
grain dust stored in agricultural yards.29 FL responsible antigens vary from country to 
country and depend on climate, farming and production conditions.39 Thermophilic 
actinomycetes, such as Saccharopolyspora rectivirgula, Thermoactinomyces vulgaris, 
Thermoactinomyces viridis and Thermoactinomyces sacchari, are the most frequently 
described agents.29,40 However, in some cases, FL disease results from fungal exposure, 
such as Alternaria, Aspergillus fumigatus and Botrytis species.41 Further, Reboux et al. 
(2006) identified Absidia corymbifera, Eurotium amstelodami and Wallemia sebi as main 
causal agents to FL in France.42 In fact, all these organisms typically reproduce at high 
humidity zones and temperatures of 40-60 ºC; therefore, this form of HP is more frequent 
in regions where agriculture predominates, especially in rainy and hot seasons.42 Despite 
the disease prevalence in exposed farmers is not well-known, several studies have 
reported similar findings, placing the prevalence in 0.5 to 4.4 %.43,44 
 
Fungal exposure 
Molds have been described for years as a common cause of occupational HP.45 In fact, a 
mold is a type of fungus that grows in damp areas; it releases tiny particles, commonly 
called as spores, that can be harmful when breathed in.46 Mold-induced HP has been 
increasingly reported as being caused by humidifiers, heating and ventilation systems 
contaminated by Aspergillus, Cladosporium, Penicillium, Aureobasidium pullulans, 
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Cephalosporium or Mucor species.45 (Table 2) However, molds can be found in other 
unexpected home reservoirs, such as fruits and vegetables, leading to various forms of 
HP, such as onion worker's lung, potato worker's lung or fruit grower´s lung;6 moldy 
tapestry with Penicillium, Cladosporium or Botrytis species;46 and even flower pots, 
whose inhalation of mold spores containing Pullularia pullulans, Trichoderma viride, 
Cephalosporium acremonium or Aspergillus fumigatus may lead to HP.47 All these 
exposure sources can go completely unnoticed in a domestic environment, and possibly 
more frequent than widely recognized. So, a thorough visit of the whole house is 
advisable in search of mold stains, even of unnoticed size, humidity, condensation or 
musty odor.45,48 
Summer-type HP (SHP) is the most common form of domestic HP in Japan, especially 
in the western and southern parts of the country, being also some cases reported in other 
Asian countries.49 SHP is caused by repeated inhalation of fungi Trichosporon species, 
namely Trichosporon cutaneum, which contaminates domestic environments, usually 
wooden houses, during hot and humid summers, and after a rainy season.49,50 
Trichosporon cutaneum develops at temperatures between 25-28 °C and a relative 
humidity above 80%, especially in the presence of wet wood or vegetation.50 An 
epidemiological study on HP performed in Japan in the 1980s showed that the proportion 
of SHP cases in patients with HP was 74.4%.51 However, more recently, Iijima et al. 
(2017) verified that the incidence seems to be decreasing, mainly due to changes in 
residential environments, although climatic conditions in any year may cause a temporary 
increase in the incidence rate.52 
Suberosis, also known as corkhandler's disease or corkworker's lung, is another form of 
HP caused by fungi existing in the working environment; it occurs in cork workers and 
has been mainly reported in Portugal.53-57 Cork oak is the second most dominant forest 
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species in Portugal, making this country the world’s leading exporter of cork, followed 
by Spain.58,59 The processes used in cork manufacture depend on the end product to be 
obtained; however, during this process, workers are exposed to a heavily contaminated 
environment with moldy cork dust.55 The most frequent cork colonizing fungi during its 
industrial processing are Penicillium glabrum (formerly known as Penicillium 
frequentans) and Chrysonilia sitophila. Penicillium glabrum is the main causative agent 
of suberosis, but during the storage period, cork can also be colonized by other fungi, 
such as Aspergillus fumigatus or Mucor species.55,56 In Portugal, it has been estimated 
that 9 to 19% of cork workers may develop suberosis.53,54 
In recent decades, several other different forms of disease caused by fungi have been 
described in the literature. HP can also be observed in individuals working with woods 
colonized by fungi, namely Aspergillus and Penicillium species, Cryptostroma corticale, 
Alternaria species, among others. The first cases were reported when conventional 
outdoor drying of wood was replaced by indoor drying in special ovens, as well as in the 
indoors wood sorting and cutting, in order to improve working conditions in sawmills.36 
Some cases have been reported in food industry workers, such as bakers who are exposed 
to flour on a daily basis, that can be contaminated with the fungi Aspergillus fumigatus;33 
cheese producers can also develop cheese workers’ HP caused by Penicillium notatum, 
Penicillium viridicutum, Aspergillus fumigatus, Aspergillus niger or Aureobasidium 
pullulans;34 in soy sauce brewer, where precipitin against Aspergillus oryzae was found 
(soya dust alveolitis);6,35 and even in salami factory workers due to inhalation of dried 
sausage dust. Morell et al. (2011), for example, described five Spanish patients working 
in dry sausage production with Salami Brusher’s disease, caused by Penicillium glabrum 
and Aspergillus fumigatus.32 
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In conclusion, fungal exposure can have various sources, variable in frequency but highly 
troublesome; so, an increasing awareness on their detection should be taken, both in any 
patient daily activities, as for instance musicians, mainly saxophonists that may inhale 
fungi Candida albicans, Phoma species or Ulocladium botrytis, presents in the instrument 
mouthpiece (Sax Lung disease).60  
 
Animal proteins exposure 
Bird fancier's lung (BFL), or bird breeder's disease, is a complex syndrome caused by the 
repeated inhalation of avian proteins through the form of bird droppings, feathers or 
secretions, triggering an exaggerated immune response to the antigen and consequent HP 
in sensitized individuals.61 Less often, the inhalation may occur from feathers of duvets 
or pillows.62 BFL is most frequently reported after exposure to pigeons and birds 
belonging to the Psittaciformes order, including cockatoos, parakeets, and parrots. Else, 
some cases of BFL resulting from poultry exposure, including chickens, turkeys, geese, 
and ducks have also been reported.30,63 (Table 3) 
The prevalence of this form of disease varies geographically, might be partially explained 
by the local climate, availability of medical resources, local cultural habits, racial factors, 
smoking habits and even exposure duration and intensity. However, it is known that BFL 
is the most common form of HP worldwide, corresponding to 66-68% of all HP forms,30 
with a prevalence ranging from 6-20% in exposed pigeon breeders.61 In Portugal, some 
studies have reported a prevalence of BFL ranging from 2 to 5%.64,65 On the other hand, 
the acute, subacute and chronic presentations of BFL have also been recognized, but often 
overlap clinically to each other. Anyway, a continuous antigen exposure in chronic phase 
presents a worse prognosis.30  
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Mycobacterial exposure 
Hot tub baths have become increasingly common in homes, as well as in hotels and spas. 
Recently, these baths have been associated with an emerging disorder, known as Hot Tub 
Lung (HTL).66  
HTL is a lung disease that can be caused by inhalation of hot water aerosols from 
hydromassage baths (the majority of cases found in literature), but can also occur in public 
recreational water facilities, such as swimming pools, saunas and spas, since these waters 
are contaminated by nontuberculous mycobacteria (NTM), in most cases belonging to the 
Mycobacterium avium complex (MAC).66,67 
MAC mainly consists of two mycobacteria species, namely Mycobacterium avium and 
Mycobacterium intracellulare.68 It is the hydrophobic nature of Mycobacterium avium 
and Mycobacterium intracellulare and the high content of mycolic acid present in their 
cell walls that makes MAC highly resistant to disinfectants commonly used in swimming 
pools and spas. They withstand temperatures up to 42°C, exceeding the higher limit of 
temperature established in spas.67 Glazer et al. (2007) reported that Mycobacterium avium 
and other NTMs were found in 72% of the air and water samples randomly collected from 
18 swimming pools; concentrations were significantly lower in chlorine and bromide 
disinfected pools than in those disinfected with hydrogen peroxide and ultraviolet light.69  
A relatively recent example of HP induced by mycobacteria is metal workers exposed to 
aerosolized metalworking fluids (MWF) contaminated with NTM, namely 
Mycobacterium chelonae and Mycobacterium immunogenum. MWF are complex 
mixtures of oil and water commonly used as refrigerants and lubricants in various 
industries.31 
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Chemical Exposure 
Chemically-induced HP is an uncommon entity; however, several substances capable of 
causing the disease have already been described.6 (Table 2) Acrylate compounds, such 
as methyl methacrylate are associated with an increased incidence of HP in dentists. This 
increase seems to be associated with the substitution of amalgam fillers by acrylate fillers 
in dental care.70 On the other hand, isocyanates are highly reactive reagents, widely used 
on polyurethane polymers production for flexible and rigid foams, such as elastomers, 
adhesives, surface coatings and paints.71 Several cases of HP caused by these reagents 
have already been reported, mainly related to spray painting or plastics manufacture.37 
Other compounds, such as anhydrides used in plastics, paints, resins, and glues, as also 
triglycidyl isocyanurate, often used in paints, are also recognized as causing HP.30,72 The 
prevalence of isocyanate-induced HP, related to the plastic manufacturing process, is 
1.3% of all chronic HPs in Japan, having only been reported three cases over a ten´s year 
period.71,73 
 
Methods for antigen determination 
The identification of the causal antigen is crucial, not only for the diagnosis but also for 
establishing preventive measures and of disease prognosis. All available tools to detect 
the source of exposure should be used.5 
 
Clinical history 
The first step is to collect a highly detailed clinical history so that it will be possible to 
uncover or to assume the exposure source, either in domestic, recreational or work setting. 
5 The use of a standardized questionnaire can be very useful in identifying exposures, 
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otherwise undetected in a more informal discussion with the patient; however, these 
questionnaires need validation prior being used in clinical practice.6  
 
Specific antibodies 
The second step requires the use of laboratory tests to confirm the presence of 
immunologic sensitization to a suspected antigen, classically using a precipitation 
reaction between patient´s sera and causal antigen extracts for detection of specific 
antibodies, mainly of the immunoglobulin G (IgG) class.5 The presence of specific IgG 
antibodies reflects an immune response to a specific exposure, indicating that the 
individual had a sufficient exposure level to the antigen to develop sensitization. 
However, in itself, this aspect is not sufficient to establish the diagnosis, since many 
asymptomatic individuals show a similar level of humoral responses.16 In fact, precipitins 
are only an exposure marker. Antibodies precipitating against potential antigens may be 
present in serum and bronchoalveolar lavage (BAL) samples from individuals with HP, 
but also in some asymptomatic exposed to the same antigens. Up to 40% of farmers 
exhibit positive serum precipitins in the absence of clinically significant manifestation of 
the disease, with no long-term squeal,3 as shown by one study evaluating 43 
asymptomatic milk producers who had serum antibodies specific for FL antigens and did 
not develop abnormal lung function tests during a 20-year follow-up period.74 
Nonetheless, a positive serum antibody testing is a significant predictor of HP (odds ratio: 
5.3; 95% confidence interval: 2.7–10.4)75 although the absence of serum precipitin does 
not exclude an HP diagnosis.2 Fenoglio et al. (2007) found that serum precipitins were 
useful for diagnosing acute HP indiced by fungi (predictive negative value, 81–88%; 
predictive positive value, 71–75%).76 There are several laboratory methods for qualitative 
determination of specific antibodies, such as the precipitation reaction of the double 
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immunodiffusion of Ouchterlony or combined with immunoelectrophoresis; as well as 
for quantitative determination, namely enzyme-linked immunosorbent assay (ELISA), 
ImmunoCAP or Immulite. In general, the results obtained using these methods differ 
considerably,77 with ELISA being nowadays the most frequently used.78-81 Sandoval et 
al. (1990), carrying out a comparative study for detection of specific antibodies in BAL 
of patients with HP, using immunoelectrophoresis and ELISA, found positivity in 12 % 
and 100 % of cases, respectively, showing its usefulness for antibodies detection against 
pigeon antigens in fluids with a low protein content.80 In another study, Simpson et al. 
(1992) revealed that the ELISA method showed greater sensitivity (nearly to 103 times 
higher) than the double-immunodiffusion method, in patients with BFL.81 Suhara et al 
(2015), also reported a high sensitivity and specificity of the antibodies, 80–100% and 
92–100%, respetively, in acute bird-related HP, claiming that antibody titers may be 
lower in chronic bird-related HP, as cellular immunity is more closely associated with 
chronic bird-related HP pathology than the humoral immunity.79  
There is a long list of potential antigens in HP, although there is only a limited number of 
available antigen preparations proposed for detection (Table 4). The selection of antigens 
to be tested should be based on the individual exposure history and in the most prevalent 
type in each region.6,77 In fact, the serum specific IgG (sIgGs) panels used in different 
centers is determined by practice location. An example of a sIgGs panel include molds, 
bacteria, animal proteins and chemical substances, as illustrated in Table 4.  
Currently, clinicians do not have access to tests that allow them to individualize the panel 
for actual exposure on their patients. In addition, the specific antibodies are not always 
identified in patients with HP, probably because some of the antigens that cause this 
condition still remains unknown.82 The finding that common peptide epitopes may induce 
cross-reactivity in HP serodiagnosis can affect this test performance, making the research 
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for epitopes that are common to different microorganisms, capable of inducing the same 
antibody response in patients with HP, a current challenge. 23 
The lack of reliable standardized techniques and of established physiological intervals for 
sIgGs levels against possible causal antigens, raise concern about the diagnostic use of 
this technique.5 Thus, it would be advantageous to involve auxiliary specialists, 
occupational physicists, and industrial or environmental hygienists, in order to obtain 
more reliable samples for microscopic, microbiological and immunological analysis.6 
However, and despite all these limitations, this technique is essential to support the HP 
diagnosis, sometimes determinant to discover new etiologies of the disease, as well as to 
differential diagnosis between HP and other diseases, such as idiopathic pulmonary 
fibrosis (IPF).74,83 
 
Specific inhalation challenge 
A third method to confirm causality between a suspected antigen and the disease is the 
specific inhalation challenge (SIC), which presupposes patient exposure to the potentially 
contaminated environment or through direct inhalation of the antigens or commercially 
available extracts.5 This technique has also been used to confirm a suspected etiologic 
agent and when there are some doubts concerning the differential diagnosis of chronic 
HP and IPF.84 The focus of SIC is to demonstrate that exposure to a particular agent 
produces a fall in forced expiratory volume in one second (FEV1), while ensuring that 
fall remains within safety limits and does not cause serious adverse reactions. Indeed, 
most authors recommend that, during SIC, exposure should be increased very gradually; 
in fact, the exposure intensity is of particular relevance to enhance SIC safety, especially 
with previously unknown sensitizing agents. In this context, it would be very useful to 
identify patient characteristics that predict a specific response during SIC.85 Morell et al. 
21 
 
(2008) proposed that SIC should be considered the “gold standard” among noninvasive 
BFL diagnostic examinations, focusing on decreased forced vital capacity (FVC) and/or 
lung diffusing capacity for carbon monoxide (DLCO). 63 In fact, this test reveals very 
satisfactory sensitivities and specificities in experienced centers. 6 In a study carried out 
by Muñoz et al. (2014), SIC evidenced a good diagnostic yield in 113 patients with 
suspected HP. The overall sensitivity and specificity were, respectively, 73 and 84 %, 
when tests against all causative agents were analyzed together; and 85 and 86 %, 
respectively, when evaluating results in patients only exposed to avian or fungal 
antigens.86 In the same way, Ishizuka et al. (2015) demonstrated that the sensitivity and 
specificity for diagnosing chronic BFL were as high as 92.9 % and 94.7%, respectively.87  
In spite of its “gold standard” status, SIC is rarely performed because it is not standardized 
nor validated, being required specialized centers with experience in the procedure and 
with proper equipment for treatment of uncommon, but potential complications.77 
 
Prevention 
Avoiding exposure to causal agent is the cornerstone of HP management and an important 
and determinant factor to prognosis, since progression is largely avoidable with adequate 
antigen eviction.3 Patients should be advised about the relevance of a clean domestic air 
environment and the absolute necessity of avoiding further exposures to known HP 
causative agents. However, this eviction is difficult for most patients due to professional 
or personal issues (e.g. affective links to a pet or fear of abandoning a hobby).6 In this 
sense, an occupational and environmental health professional should carefully recognize 
individuals at risk, identified through a detailed history and exposure’s evaluation in the 
workplace, and also collaborate with partners in the local community and employers to 
raise awareness about the risks of antigen exposure, and even inform them about 
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preventive measures. Providing simple and accessible educational material can also help 
to reduce exposure and to facilitate more accurate diagnosis, as well as to incite the use 
of personal protective equipment, including masks and respirators.88 
In the specific case of FL exposure, there are three possibilities for reducing repeated 
inhalation of organic particles and, thus preventing progression to a fibrosing process: 1) 
definitive withdrawal of patient from workplace, which in most situations is not a feasible 
solution due to economic issues; 2) improve the storage methods of hay or straw; it has 
been shown that provision in low-density bundles hinders the growth of microorganisms, 
rather than round bales with a high concentration of moisture due to the increased hay 
compaction; 3) use high efficient respiratory protection devices capable of preventing the 
entry of antigens into the bronchial tree.29 In the case of pigeon breeders, they may be 
encouraged to spend less time in the loft, and to wear a coat and hat to be removed when 
exiting the loft, so as to avoid continuous contact with the antigen that can be carried on 
clothing or hair. Increasing the level of ventilation in the loft can also be useful in reducing 
antigen exposure.16 Regarding HTL, World Health Organization recommends that 
treatment and prevention methods of HP caused by Mycobacterium avium should include 
protection, coagulation, flocculation, sedimentation, filtration, disinfection and protection 
of water distribution system.67 
 
Prognosis 
HP evolution is highly variable and depends essentially on the time and concentration of 
antigen exposure. Idividuals with the acute form of disease, but who had early detection 
and an immediate eviction of the causal antigen, tend to have an excellent prognosis. In 
chronic forms, a partial recovery may also occur; however, in some cases, the disease 
tends to progress, leading to a permanent loss of lung function, irreversible pulmonary 
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fibrosis and death, even after antigen eviction and appropriate treatment.6,90 For example, 
about 20% of the acute forms of FL evolve into chronic forms, hence into irreversibility 
29 and fatal HP cases have been reported to be related to acute exacerbations after chronic 
exposure to some antigens, namely avian protein antigens, thermophilic actinomycetes, 
molds, heated plastics, among others.71,90,91 
Mortality data are scarce in the literature; however, in England and Wales, from 1968 to 
2008, 878 HP deaths were reported,92 while in a study performed in Denmark, 5-years 
survival rate was 93%.7 In chronic HP, the average survival rate is of 7 years.1 
Factors associated with a poor prognosis include longer exposure period, high-intensity 
antigen exposure, advanced age, smoking, and a radiological and/or histological pattern 
with fibrosis.1,6,20,89,93 The antigen type may also influence the prognosis, as there is some 
data suggesting that BFL may have a worse prognosis than FL.5 However, Braun et al. 
(1979) suggest that exacerbations/relapses are the factors that most influence a 
detrimental evolution at long-term.94 Further, Fernandez-Pérez et al. (2013) following up 
142 HP cases reported that the non-identification of antigen was associated with a 
decrease in survival from 18.2 to 9.3 years.38 
 
Conclusion 
HP occurs only in a small number of individuals exposed to causal antigens. Most 
individuals are only sensitized, since the development of the disease is based on the 
interaction between inducing factors (causal antigen) and promoters, itself related to the 
host (genetic background and additional environmental factors), leading to dysregulation 
of the immunity system and consequent persistent inflammation. 
Several forms of the disease have been described, being the most common caused by the 
inhalation of bacteria, proteins, fungi, or mycobacteria present in the host environment, 
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such as workplace, home environment or recreational activities. Other substances, such 
as chemicals (namely, isocyanates or acrylates) may also act as triggering agents, despite 
less commonly associated with the disease.  
The diagnosis of HP should be based on a proactive search for potential antigen sources, 
whose identification is often hampered by the unrecognition of some sources and/or by 
the lack of standardized detection methods of sensitization. In this context, it would be 
legitimate to create multidisciplinary Public Health teams to collect and to evaluate in 
locus potentially suspicious material.  
Eviction of the causal agent exposure is the cornerstone of HP management, since antigen 
inhalation maintenance has prognostic implications, with the consequent progression and 
reduction of survival rate. In this way, protection measures should be implemented, in 
particular at the individual level or at the exposure source itself. A longer exposure period 
and of high antigenic intensity, the type of antigen and the non-identified exposure source 
are associated with a reserved prognosis. 
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Figure 1. Pathogenesis of hypersensitivity pneumonitis (HP). (A) Classical immunopathological mechanisms proposed for HP (adapted from 
Delgado et al. 95) (B) Persistent antigen exposure and sensitization associates with local antigen-antibody complex deposition, macrophage 
activation, mononuclear cell recruitment and predominant Th1 cell-mediated response; continuous exposure leads to critical changes in the lung, 
ending in fibrosis. 4,17 
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Table 1. Clinical classification of hypersensitivity pneumonitis. 1,16 
HP, hypersensitivity pneumonitis 
  
 Acute/subacute HP Chronic HP 
Exposure to causal antigen  Intermittent high-level exposure (the subacute form 
develops more insidiously and it is caused by a more 
prolonged and less intense exposure to the agent 
compared with the acute form) 
Continuous low-level exposure 
Onset of symptoms 4-8 hours or days after exposure Insidious, over weeks to months 
Signs and symptoms Cough, dyspnea, asthenia, malaise and fever Cough, dyspnea, asthenia and weight loss 
Physical examination Bilateral widespread crackles; sometimes 
auscultation is normal 
Inspiratory crackles, cyanosis, and cor pulmonale  
Outcome  Symptoms decrease in a few hours or even days, 
after eviction of causative agent. Exacerbations may 
occur when the subject is again exposed to the 
allergen-containing environment 
End-stage fibrotic disease and/or emphysema 
Exacerbations may occur despite avoidance of 
exposure 
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Table 2. Causal antigens of hypersensitivity pneumonitis. 4,6,34,55,56 
Specific antigens Sources Type of disease 
Bacteria 
Acinetobacter spp. Contaminated water, contaminated machine fluid Machine operator’s lung 
Achromobacter Contaminated humidifiers Humidifier lung 
Bacillus spp. Contaminated humidifier water, sawdust, moist Woodworker’s lung, humidifier lung 
Erwinia herbícola  
Lichtheimia corymbifera  
Saccharopolyspora rectivirgula  
Streptomyces thermohygroscopicus  
Thermoactinomyces vulgaris 
Thermoactinomyces viridis  
Thermoactinomyces sacchari  
Moldy hay, grain Farmer’s lung 
Streptomyces albus Contaminated compost, edible mushroom manure, hay 
dusty soil 
Farmer’s lung, mushroom grower’s lung 
Thermoactinomyces sacchari Moldy sugarcane, hay, straw, moldy plants Bagassosis, Farmer’s lung 
Fungi/yeasts 
Absidia corymbifera Hay, straw, plant material, contaminated humidifiers Farmer’s lung, humidifier lung 
Alternaria alternata Contaminated humidifiers, wood pulp, dust Humidifier lung, woodworker’s lung 
Aspergillus spp. (e.g. A. fumigatus, A. 
niger) 
Contaminated barley, hay, straw, moldy plants, 
mushrooms, cheese. Contaminated houses, humidifiers, 
molds on the walls 
Farmer´s lung, Mushrooms worker’s lung, 
Cheese workers' HP; Domestic HP, 
Humidifier lung 
Aspergillus oryzae Aspergillus enzyme in baking agents, soy Fungal alveolitis, soya dust alveolitis 
Aureobasidium spp. Contaminated sauna water, domestic ventilation and 
cooling systems, steam iron water, potted flowers, 
greenhouse 
Humidifiers lung, indoor fountain HP, sauna 
taker's lung, steam iron lung 
Botrytis cinerea Mold on grapes Wine-grower's lung 
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Candida albicans Saxophone Sax lung 
Cephalosporium spp. Contaminated basement, contaminated humidifier, potted 
flowers, greenhouse 
Humidifier lung, Japanese summer-type HP 
Chrysonilia sitophila Moldy cork Suberosis 
Cryptococcus albidus, C. neoformans Contaminated houses Summer type HP 
Cladosporium herbarum, C. 
cladosporioides 
Mold on ceiling Mold alveolitis, indoor air HP, Hot-tub lung 
Eurotium amstelodami Contaminated humidifiers, hay Humidifier lung, Farmer's lung 
Fusarium culmorum Ultrasound nebulizers Indoor fountain HP 
Fusarium spp. Molds in living and working spaces, molds on plants Indoor air alveolitis; humidifier lung 
Mucor spp.  Moldy wood, contaminated humidifiers, sawdust Woodworker´s lung; cork worker´s lung, 
humidifier 
Mucor stolonifer Moldy paprika pods Paprika slicer´s lung historical 
Penicillium casei Moldy cheese, white coating on salami, contaminated 
humidifiers 
Cheese washer’s lung, humidifiers lung, 
salami producer’s lung 
Penicillium glabrum Moldy cork, white coating on salami, molds in 
apartments 
Salami producer’s lung, cork worker’s lung 
(suberosis), summer-type HP 
Penicillium spp. Contaminated basement, moldy cork, molds on fruits and 
vegetables 
Basement lung, onion worker's lung, potato 
worker's lung, fruit grower´s lung, suberosis 
Saccharomyces cerevisiae Baker’s yeasts, brewer’s yeasts, wine yeasts Farmer´s lung, yeast powder alveolitis 
Trichosporon cutaneum Contaminated houses Summer-type HP 
Trochoderma viridae Molds in ultrasound nebulizers, potted flowers, 
greenhouses, mold on wood, paper, citrus fruits 
Indoor air alveolitis, humidifier lung 
Wallemia sebi Hay, straw, plant material Farmer's lung 
Mycobacteria 
NTM (Mycobacterium immunogenum, 
M. avium complex, M. chelonae, M. 
fortuitum, M. abscessus) 
Contaminated machine fluids, cutting fluids, cutting oils, 
wind instruments, contaminated water, whirlpools 
Hot tub lung, Whirlpool alveolitis, Machine 
operator’s lung, wind instrument alveolitis 
Animal proteins 
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Animal fur dust Animal pelts Furrier’s lung 
Avian droppings, serum and feathers Parakeets, canaries, budgerigars, pigeons, parrots, 
chicken, turkeys, geese, ducks, wild birds, pheasants 
Bird fancier’s lung 
Avian feathers Feathers beds, pillows, duvets Feather duvet lung 
Fish meal Animal feed Fish meal alveolitis 
Protozoans Contaminated air conditioners Humidifier lung 
Plant proteins 
Grain flour (wheat, rye, oats, maize) Flour dust Flour dust alveolitis 
Legumes (soy) Legumes (soy)  Soya dust alveolitis 
Paprika  Paprika dust Paprika splitters lung 
Chemicals 
Acid anhydrides  
Isocyanates 
Polyurethane foams, spray paints, elastomers, glues, 
adhesives, mattress, car parts, shoes, elastic synthetic 
fibers 
Acid anhydride alveolitis, isocyanate 
alveolitis 
Chloroethylene Degreasing agents, cleaning agents, extraction agents Chemical alveolitis 
Methyl methacrylate Dental materials, lacquer, resin, glues Methacrylate alveolitis 
Triglycidyl isocyanate Powder paints, polyester powder Pinter’s lung 
Metals 
Beryllium Batteries, computers neon Beryliosis 
Cobalt Hard metal alloys Hard metal lung disease 
Zinc Zinc fumes Zinc fumes alveolitis 
HP, hypersensitivity pneumonitis; NTM, nontuberculous mycobacteria.
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Table 3. Birds associated with bird fancier's lung. 30 
Order Animals 
Anseriformes Ducks  
Geese 
Columbiformes Pigeons 
Galliformes Chickens 
Partridges 
Pheasants 
Turkeys 
Passeriformes Canaries 
Psitacciformes Budgerigars 
Cockatoos 
Parrots 
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Table 4. Some common antigen panels and mixtures available for specific IgG 
quantification to evaluate exposure/sensitization in suspected hypersensitivity 
pneumonitis. (adapted from Vasakova et al. )6 
 
 
 
 
Microorganism-related antigens 
Indoor Molds mix 1: Penicilium notatum, Cladosporium herbatum, Aspergillus fumigatus, 
Alternaria alternata 
Indoor Molds mix 2: Penicilium chrysogenum, Cladosporium herbatum, Mucor racemosus, 
Alternaria alternata 
Aspergillus spp mix: Aspergillus fumigatus, A. terreus, A. niger, A. flavus 
Farm microorganisms mix: Micropolyspora faeni, Thermoactinomyces vulgaris 
Alternaria alternata 
Aspergillus fumigatus 
Cladosporium herbatum 
Penicillium glabrum (frequentans) 
Micropolyspora faeni 
Thermoactinomyces vulgaris 
Bird-related antigens 
Poultry feathers mix: goose, hen, duck, turkey 
Cage bird feather mix: parrot, budgerigar, canary, alexander, finch 
Bird feathers mix: goose, hen, ducks, parrot 
Budgerigar antigens: feather, droppings, serum 
Pigeon antigens: feather, droppings, serum 
Parrot antigens: feather, droppings, sera 
Pigeon serum 
Pigeon feathers 
Canary feathers 
Chemical antigens/haptens 
Paint polyester chemicals mix: Toluen diisocyanate, Difenylmetan diisocyanate,  
Hexametylen diisocyanate, Phthalic anhydride 
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ANEXO 
 
PULMONOLOGY - GUIDE FOR AUTHORS 
 
Types of article 
Articles on original research: The text must not exceed 2500 words, excluding 
references and tables, and be organized into introduction, methods, results, discussion and 
conclusions, with a maximum of 4 tables and/or figures. In the materials and methods 
there must be a complete and appropriate reference to the statistical methods used and the 
results should be quite sufficiently explicit. 
Review articles: Pulmonology publishes primarily review articles which have been 
requested by the editors. However, unsolicited articles submitted will be considered, 
particularly systematic reviews (meta-analysis). The text must not exceed 5000 words, 
excluding references and tables, with a maximum of 5 tables and/or figures in total. The 
reviews must be organized systematically in introduction, methods, results and 
discussion. 
Short publications: Preliminary results or new findings could lead to short publications. 
The text should not exceed 1000 words, excluding references and tables, and be organized 
into introduction, methods, results and discussion, with a maximum of 2 tables and/or 
figures in total and up to 10 references. The short publications should be submitted with 
formal abstracts in English, of not more than 250 words. 
Commentaries: Commentaries, essays, critical analyses or declarations of a position in 
relation to topics of interest in the area of health, particular the politics of health and 
medical education will be considered. The text must not exceed 900 words, excluding 
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references and tables, and include a maximum of one table or figure. Commentaries do 
not require abstracts; they will normally be at the request of the editors. 
Special articles: Where appropriate the editorial board may invite one or various authors 
to write an article on a subject of particular formative interest in achieving the priorities 
of the journal and where the subject matter is not being addressed by other areas of study 
(for example postgraduate study). 
Clinical case studies (case reports): The text should not exceed 1200 words, excluding 
references and tables, with a maximum of 2 tables and/or figures in total. Clinical case 
studies should be submitted with formal abstracts in English, of not more than 120 words. 
Depending on their interest and originality the clinical case studies may include a 
commentary/discussion by one of the editors or by an invited reviewer (Clinical case 
study with discussion). 
Letters to the editor: Two types of letter to the editor are considered, clinical notes and 
correspondence.  
Clinical notes stand for a very objective reporting of results of clinical observation or 
original research for which a detailed development is not appropriate. The text should not 
exceed 800 words, excluding references and tables, and can include a maximum of two 
tables or figures and up to 7 references. 
Correspondence refers to a succinct commentaries on articles published in the Portuguese 
Journal of Pulmonology, preferably within the previous 6 months. In this case, the text 
should not exceed 500 words, excluding references and tables, and can include a 
maximum of one table or figure and up to 5 references.  
Letters to the editor should not include abstracts. 
In manuscripts signed by more than 6 authors (3 authors in the case of letters to the editor), 
there has to be an explicit explanation for such an extensive authorship.  
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Manuscripts submitted to the Pulmonology must conform to the recommendations 
indicated here and must be accompanied by a covering letter. The Editorial Board will 
acknowledge receipt of manuscripts, supplying information as to the orientation category 
given to the relevant article. Whenever there are editorial recommendations to changes to 
the manuscripts sent, the authors should supply a new version with an explanation of 
changes made. Correspondence between the authors and the journal should be conducted 
electronically, by the Elsevier Editorial System (http://ees. elsevier.com/pulmoe). 
 
Submission checklist 
You can use this list to carry out a final check of your submission before you send it to 
the journal for review. Please check the relevant section in this Guide for Authors for 
more details. 
Ensure that the following items are present: 
One author has been designated as the corresponding author with contact details: 
• E-mail address 
• Full postal address 
All necessary files have been uploaded: 
Manuscript: 
• Include keywords 
• All figures (include relevant captions) 
• All tables (including titles, description, footnotes) 
• Ensure all figure and table citations in the text match the files provided 
• Indicate clearly if color should be used for any figures in print  
Graphical Abstracts / Highlights files (where applicable)  
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Supplemental files (where applicable)  
Further considerations 
• Manuscript has been 'spell checked' and 'grammar checked' 
• All references mentioned in the Reference List are cited in the text, and vice versa 
• Permission has been obtained for use of copyrighted material from other sources 
(including the Internet) 
• Relevant declarations of interest have been made 
• Journal policies detailed in this guide have been reviewed 
• Referee suggestions and contact details provided, based on journal requirements 
 
For further information, visit our Support Center. 
 
BEFORE YOU BEGIN 
Ethics in publishing 
Please see our information pages on Ethics in publishing and Ethical guidelines for jornal 
publication. 
 
Human and animal rights 
If the work involves the use of human subjects, the author should ensure that the work 
described has been carried out in accordance with The Code of Ethics of the World 
Medical Association (Declaration of Helsinki) for experiments involving humans; 
Uniform Requirements for manuscripts submitted to Biomedical journals. Authors should 
include a statement in the manuscript that informed consent was obtained for 
experimentation with human subjects. The privacy rights of human subjects must always 
be observed. 
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All animal experiments should comply with the ARRIVE guidelines and should be 
carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and 
associated guidelines, EU Directive 2010/63/EU for animal experiments, or the National 
Institutes of Health guide for the care and use of Laboratory animals (NIH Publications 
No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that 
such guidelines have been followed. 
 
Declaration of interest 
All authors must disclose any financial and personal relationships with other people or 
organizations that could inappropriately influence (bias) their work. Examples of 
potential conflicts of interest include employment, consultancies, stock ownership, 
honoraria, paid expert testimony, patent applications/registrations, and grants or other 
funding. If there are no conflicts of interest then please state this: 'Conflicts of interest: 
none'. More information. 
 
Submission declaration and verification 
Submission of an article implies that the work described has not been published 
previously (except in the form of an abstract or as part of a published lecture or academic 
thesis or as na electronic preprint, see 'Multiple, redundant or concurrent publication' 
section of our ethics policy for more information), that it is not under consideration for 
publication elsewhere, that its publication is approved by all authors and tacitly or 
explicitly by the responsible authorities where the work was carried out, and that, if 
accepted, it will not be published elsewhere in the same form, in English or in any other 
language, including electronically without the written consent of the copyright-holder. To 
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verify originality, your article may be checked by the originality detection service 
CrossCheck. 
 
Authorship 
All authors should have made substantial contributions to all of the following: (1) the 
Conception and design of the study, or acquisition of data, or analysis and interpretation 
of data, (2) drafting the article or revising it critically for important intellectual content, 
(3) final approval of the version to be submitted. 
 
Changes to authorship 
Authors are expected to consider carefully the list and order of authors before submitting 
their manuscript and provide the definitive list of authors at the time of the original 
submission. Any addition, deletion or rearrangement of author names in the authorship 
list should be made only before the manuscript has been accepted and only if approved 
by the journal Editor. To request such a change, the Editor must receive the following 
from the corresponding author: (a) the reason for the change in author list and (b) 
written confirmation (e-mail, letter) from all authors that they agree with the addition, 
removal or rearrangement. In the case of addition or removal of authors, this includes 
confirmation from the author being added or removed. Only in exceptional circumstances 
will the Editor consider the addition, deletion or rearrangement of authors after the 
manuscript has been accepted. While the Editor considers the request, publication of the 
manuscript will be suspended. If the manuscript has already been published in an online 
issue, any requests approved by the Editor will result in a corrigendum. 
 
Clinical trial results 
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In line with the position of the International Committee of Medical Journal Editors, the 
jornal will not consider results posted in the same clinical trials registry in which primary 
registration resides to be prior publication if the results posted are presented in the form 
of a brief structured (less than 500 words) abstract or table. However, divulging results in 
other circumstances (e.g., investors' meetings) is discouraged and may jeopardise 
consideration of the manuscript. Authors should fully disclose all posting in registries of 
results of the same or closely related work. 
 
Reporting clinical trials 
Randomized controlled trials should be presented according to the CONSORT guidelines. 
At manuscript submission, authors must provide the CONSORT checklist accompanied 
by a flow diagram that illustrates the progress of patients through the trial, including 
recruitment, enrollment, randomization, withdrawal and completion, and a detailed 
description of the randomization procedure. The CONSORT checklist and template flow 
diagram are available online. 
 
Registration of clinical trials 
Registration in a public trials registry is a condition for publication of clinical trials in this 
jornal in accordance with International Committee of Medical Journal Editors 
recommendations. Trials must register at or before the onset of patient enrolment. The 
clinical trial registration number should be included at the end of the abstract of the article. 
A clinical trial is defined as any research study that prospectively assigns human 
participants or groups of humans to one or more health-related interventions to evaluate 
the effects of health outcomes. Health-related interventions include any intervention used 
to modify a biomedical or health-related outcome (for example drugs, surgical 
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procedures, devices, behavioural treatments, dietary interventions, and process-of-care 
changes). Health outcomes include any biomedical or health-related measures obtained 
in patients or participants, including pharmacokinetic measures and adverse events. 
Purely observational studies (those in which the assignment of the medical intervention 
is not at the discretion of the investigator) will not require registration. 
 
Copyright 
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing 
Agreement' (see more information on this). An e-mail will be sent to the corresponding 
author confirming receipt of the manuscript together with a 'Journal Publishing 
Agreement' form or a link to the online version of this agreement. 
 
Author rights 
As an author you (or your employer or institution) have certain rights to reuse your work. 
More information. 
 
Elsevier supports responsible sharing 
Find out how you can share your research published in Elsevier journals. 
 
Role of the funding source 
You are requested to identify who provided financial support for the conduct of the 
research and/or preparation of the article and to briefly describe the role of the sponsor(s), 
if any, in study design; in the collection, analysis and interpretation of data; in the writing 
of the report; and in the decision to submit the article for publication. If the funding 
source(s) had no such involvement then this should be stated. 
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If no funding has been provided for the research, please include the following sentence: 
This research did not receive any specific grant from funding agencies in the public, 
commercial, or not-for-profit sectors. 
 
Funding body agreements and policies 
Elsevier has established a number of agreements with funding bodies which allow authors 
to comply with their funder's open access policies. Some funding bodies will reimburse 
the author for the Open Access Publication Fee. Details of existing agreements are 
available online. 
 
Open access 
This is an open access journal: all articles will be immediately and permanently free for 
everyone to read and download. To provide open access, this journal has an open access 
fee (also known as an article publishing charge APC) which needs to be paid by the 
authors or on their behalf e.g. by their research funder or institution. Permitted third party 
(re)use is defined by the following Creative Commons user licenses: 
 
Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) For non-
commercial purposes, lets others distribute and copy the article, and to include in a 
collective work (such as an anthology), as long as they credit the author(s) and provided 
they do not alter or modify the article. 
No fee is payable by the author as publishing costs are covered by the society. 
 
Elsevier Publishing Campus 
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The Elsevier Publishing Campus (www.publishingcampus.com) is an online platform 
offering free lectures, interactive training and professional advice to support you in 
publishing your research. The College of Skills training offers modules on how to prepare, 
write and structure your article and explains how editors will look at your paper when it 
is submitted for publication. Use these resources, and more, to ensure that your 
submission will be the best that you can make it. 
 
Language (usage and editing services) 
Please write your text in good English (American or British usage is accepted, but not a 
mixture of these). Authors who feel their English language manuscript may require 
editing to eliminate possible grammatical or spelling errors and to conform to correct 
scientific English may wish to use the English Language Editing service available from 
Elsevier's WebShop. 
 
Informed consent and patient details 
Studies on patients or volunteers require ethics committee approval and informed consent, 
which should be documented in the paper. Appropriate consents, permissions and releases 
must be obtained where an author wishes to include case details or other personal 
information or images of patients and any other individuals in an Elsevier publication. 
Written consents must be retained by the author and copies of the consents or evidence 
that such consents have been obtained must be provided to Elsevier on request. For more 
information, please review the Elsevier Policy on the Use of Images or Personal 
Information of Patients or other Individuals. Unless you have written permission from the 
patient (or, where applicable, the next of kin), the personal details of any patient included 
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in any part of the article and in any supplementary materials (including all illustrations 
and videos) must be removed before submission. 
 
Submission 
Our online submission system guides you stepwise through the process of entering your 
article details and uploading your files. The system converts your article files to a single 
PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required 
to typeset your article for final publication. All correspondence, including notification of 
the Editor's decision and requests for revision, is sent by e-mail. 
 
Submit your article 
Please submit your article via http://ees.elsevier.com/pulmoe 
 
All manuscripts are evaluated by members of the editorial board of the journal and 
acceptance for publication of articles or original research, clinical reports or series of case 
studies which are accepted, are subject to a technical assessment by the editorial board. 
In this evaluation process articles may be: 
a) Accepted without alteration 
b) Accepted after suggested modifications have been agreed by the authors 
c) Refused 
Modifications and revisions – In the case of articles being accepted subject to 
modifications, changes must be made by the author within fifteen days (for “minor” 
modifications) or 2 months (for “major” modifications). The proof reading will be the 
responsibility of the Editorial Board unless the authors indicate otherwise. In the latter 
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case the changes must be made within the time limit set by the Editorial Board, to comply 
with. 
 
PREPARATION 
Double-blind review 
This journal uses double-blind review, which means the identities of the authors are 
concealed from the reviewers, and vice versa. More information is available on our 
website. To facilitate this, please include the following separately: 
Title page (with author details): This should include the title, authors' names and 
affiliations, and a complete address for the corresponding author including an e-mail 
address. 
Blinded manuscript (no author details): The main body of the paper (including the 
references, figures, tables and any Acknowledgements) should not include any 
identifying information, such as the authors' names or affiliations. 
Use of word processing software 
It is important that the file be saved in the native format of the word processor used. The 
texto should be in single-column format. Keep the layout of the text as simple as possible. 
Most formatting codes will be removed and replaced on processing the article. In 
particular, do not use the word processor's options to justify text or to hyphenate words. 
However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if 
you are using a table grid, use only one grid for each individual table and not a grid for 
each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text 
should be prepared in a way very similar to that of conventional manuscripts (see also the 
Guide to Publishing with Elsevier). Note that source files of figures, tables and text 
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graphics will be required whether or not you embed your figures in the text. See also the 
section on Electronic artwork. 
To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 
'grammarcheck' functions of your word processor. 
 
Article structure 
Subdivision - unnumbered sections 
Divide your article into clearly defined sections. Each subsection is given a brief heading. 
Each heading should appear on its own separate line. Subsections should be used as much 
as possible when cross-referencing text: refer to the subsection by heading as opposed to 
simply 'the text'. 
 
Introduction 
State the objectives of the work and provide an adequate background, avoiding a detailed 
literature survey or a summary of the results. 
 
Material and methods 
Provide sufficient detail to allow the work to be reproduced. Methods already published 
should be indicated by a reference: only relevant modifications should be described. 
 
Results 
Results should be clear and concise. 
 
Discussion 
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This should explore the significance of the results of the work, not repeat them. A 
combined Results and Discussion section is often appropriate. Avoid extensive citations 
and discussion of published literature. 
 
Conclusions 
The main conclusions of the study may be presented in a short Conclusions section, which 
may stand alone or form a subsection of a Discussion or Results and Discussion section. 
 
Appendices 
If there is more than one appendix, they should be identified as A, B, etc. Formulae and 
equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; 
in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; 
Fig. A.1, etc. 
 
Essential title page information 
• Title. Concise and informative. Titles are often used in information-retrieval systems. 
Avoid abbreviations and formulae where possible. 
• Author names and affiliations. Please clearly indicate the given name(s) and family 
name(s) of each author and check that all names are accurately spelled. Present the 
authors' affiliation addresses (where the actual work was done) below the names. Indicate 
all affiliations with a lower-case superscript letter immediately after the author's name 
and in front of the appropriate address. Provide the full postal address of each affiliation, 
including the country name and, if available, the e-mail address of each author. 
58 
 
• Corresponding author. Clearly indicate who will handle correspondence at all stages 
of refereeing and publication, also post-publication. Ensure that the e-mail address is 
given and that contact details are kept up to date by the corresponding author. 
• Present/permanent address. If an author has moved since the work described in the 
article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') 
may be indicated as a footnote to that author's name. The address at which the author 
actually did the work must be retained as the main, affiliation address. Superscript Arabic 
numerals are used for such footnotes. 
 
Abstract 
A concise and factual abstract is required. The abstract should state briefly the purpose of 
the research, the principal results and major conclusions. An abstract is often presented 
separately from the article, so it must be able to stand alone. For this reason, References 
should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard 
or uncommon abbreviations should be avoided, but if essential they must be defined at 
their first mention in the abstract itself. 
 
Structured abstract 
A structured abstract, by means of appropriate headings, should provide the context or 
background for the research and should state its purpose, basic procedures (selection of 
study subjects or laboratory animals, observational and analytical methods), main 
findings (giving specific effect sizes and their statistical significance, if possible), and 
principal conclusions. It should emphasize new and important aspects of the study or 
observations. 
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The headings will consist of: «Introduction and Objectives», «Patients or Materials and 
Methods», «Results» and «Conclusions». 
 
Keywords 
Immediately after the abstract, provide a maximum of 6 keywords, using British spelling 
and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 
'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may 
be eligible. These keywords will be used for indexing purposes. 
 
Abbreviations 
Define abbreviations that are not standard in this field in a footnote to be placed on the 
first page of the article. Such abbreviations that are unavoidable in the abstract must be 
defined at their first mention there, as well as in the footnote. Ensure consistency of 
abbreviations throughout the article. 
 
Acknowledgements 
Collate acknowledgements in a separate section at the end of the article before the 
references and do not, therefore, include them on the title page, as a footnote to the title 
or otherwise. List here those individuals who provided help during the research (e.g., 
providing language help, writing assistance or proof reading the article, etc.). 
 
Formatting of funding sources 
List funding sources in this standard way to facilitate compliance to funder's 
requirements: 
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Funding: This work was supported by the National Institutes of Health [grant numbers 
xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and 
the United States Institutes of Peace [grant number aaaa]. 
It is not necessary to include detailed descriptions on the program or type of grants and 
awards. When funding is from a block grant or other resources available to a university, 
college, or other research institution, submit the name of the institute or organization that 
provided the funding. 
If no funding has been provided for the research, please include the following sentence: 
This research did not receive any specific grant from funding agencies in the public, 
commercial, or not-for-profit sectors. 
 
Units 
Follow internationally accepted rules and conventions: use the international system of 
units (SI). If other units are mentioned, please give their equivalent in SI. 
 
Math formulae 
Please submit math equations as editable text and not as images. Present simple formulae 
in line with normal text where possible and use the solidus (/) instead of a horizontal line 
for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. 
Powers of e are often more conveniently denoted by exp. Number consecutively any 
equations that have to be displayed separately from the text (if referred to explicitly in the 
text). 
 
Embedded math equations 
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If you are submitting an article prepared with Microsoft Word containing embedded math 
equations then please read this related support information. 
 
Artwork 
Image manipulation 
Whilst it is accepted that authors sometimes need to manipulate images for clarity, 
manipulation for purposes of deception or fraud will be seen as scientific ethical abuse 
and will be dealt with accordingly. For graphical images, this journal is applying the 
following policy: no specific feature within an image may be enhanced, obscured, moved, 
removed, or introduced. Adjustments of brightness, contrast, or color balance are 
acceptable if and as long as they do not obscure or eliminate any information present in 
the original. Nonlinear adjustments (e.g. changes to gamma settings) must be disclosed 
in the figure legend. 
 
Electronic artwork 
General points 
• Make sure you use uniform lettering and sizing of your original artwork. 
• Embed the used fonts if the application provides that option. 
• Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, 
Symbol, or use fonts that look similar. 
• Number the illustrations according to their sequence in the text. 
• Use a logical naming convention for your artwork files. 
• Provide captions to illustrations separately. 
• Size the illustrations close to the desired dimensions of the published version. 
• Submit each illustration as a separate file. 
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A detailed guide on electronic artwork is available. 
You are urged to visit this site; some excerpts from the detailed information are 
given here. 
 
Formats 
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, 
Excel) then please supply 'as is' in the native document format. 
Regardless of the application used other than Microsoft Office, when your electronic 
artwork is finalized, please 'Save as' or convert the images to one of the following formats 
(note the resolution requirements for line drawings, halftones, and line/halftone 
combinations given below): 
EPS (or PDF): Vector drawings, embed all used fonts. 
TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 
dpi. 
TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a 
minimum of 1000 dpi. 
TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a 
minimum of 500 dpi. 
Please do not: 
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these 
typically have a low number of pixels and limited set of colors; 
• Supply files that are too low in resolution; 
• Submit graphics that are disproportionately large for the content. 
 
Color artwork 
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Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or 
PDF) or MS Office files) and with the correct resolution. If, together with your accepted 
article, you submit usable color figures then Elsevier will ensure, at no additional charge, 
that these figures will appear in color online (e.g., ScienceDirect and other sites). Further 
information on the preparation of electronic artwork. 
 
Illustration services 
Elsevier's WebShop offers Illustration Services to authors preparing to submit a 
manuscript but concerned about the quality of the images accompanying their article. 
Elsevier's expert illustrators can produce scientific, technical and medical-style images, 
as well as a full range of charts, tables and graphs. Image 'polishing' is also available, 
where our illustrators take your image(s) and improve them to a professional standard. 
Please visit the website to find out more. 
 
Figure captions 
Ensure that each illustration has a caption. Supply captions separately, not attached to the 
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Tables 
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to the relevant text in the article, or on separate page(s) at the end. Number tables 
consecutively in accordance with their appearance in the text and place any table notes 
below the table body. 
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table cells. 
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